Daily Market Reports From CapitalHeight

Daily Market Reports From CapitalHeight
Market commentary
Indices settled in the red for the third session in a row amid lingering liquidity concerns, a fresh fall in the rupee and a jump in crude oil. The Nifty ended the session below 10,250-mark, while the Sensex shed over 180 points. Against this, the market had a strong start, with the Sensex and Nifty having risen a percent each.

At the close of market hours, the Sensex closed down 181.25 points (0.53%) at 34134.38, while the Nifty fell 58.20 points (0.56%) at 10245.30. The market breadth was negative as 832 shares advanced, against a decline of 1,758 shares, while 980 shares were unchanged.

                                  Nifty 50 Index
Nifty 50 Index by CapitalHeight


Market Highlight
Maruti Suzuki India (MSI) maintained its leadership position in the domestic passenger vehicles (PV) segment in September, with seven of its models appearing in the top 10 selling list, according to the SIAM data.

Rival Hyundai Motor India also made its presence felt with three of its models featuring in the list.
According to the data compiled by the Society of Indian Automobile Manufacturers (SIAM), MSI's premium hatchback Swift stood at the first position with sale of 22,228 units in September as against 13,193 units, a year ago.

The board at India's Infrastructure Leasing and Financial Services Ltd (IL&FS) said on Monday it has appointed two advisers for assisting them in its debt resolution exercise.

The newly appointed board has chosen advisory firms, Arpwood Capital and JM Financial Consultants, which will provide financial and transaction advisory as well as "undertake valuations across divestments and monetization", the company said.

 The six-member IL&FS board was formed to revive the financier and infrastructure developer, which has 348 subsidiaries and 910 billion rupees ($12.4 billion) of debt. In a court-led process earlier this month, the government replaced the entire board with its own set of people in order to find an early resolution to a debt-default driven crisis.

Jubilant Life Sciences on Monday reported 67.18 percent rise in consolidated net profit to Rs 209.77 crore for the quarter ended September 30, mainly on account of robust sales in the pharma segment.

The company had posted a net profit of Rs 125.47 crore in the year-ago period, Jubilant Life said in a filing to BSE.Total revenue from operations stood at Rs 2,269.49 crore for the reported quarter. It was Rs 1,642.04 crore for the same period a year ago.

For Expert Advice Click here: CapitalHeight.